ARTL (Artelo Biosciences) 5-Year EBITDA Growth Rate: 31.30% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTL Artelo Biosciences Inc ARTL
31 GF Score
Price $1.15
! 2 Warning Signs
View Full Analysis

What is Artelo Biosciences 5-Year EBITDA Growth Rate?

Artelo Biosciences ARTL +2.68% 31 5-Year EBITDA Growth Rate is 31.30% as of Mar. 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Artelo Biosciences's EBITDA per Share for the three months ended in Mar. 2026 was $-3.84.

During the past 3 years, the average EBITDA Per Share Growth Rate was 17.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 31.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Artelo Biosciences was 45.70% per year. The lowest was -399.90% per year. And the median was 17.00% per year.

Artelo Biosciences  (NAS:ARTL) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Artelo Biosciences 5-Year EBITDA Growth Rate Related Terms

ARTL vs REVB, MTNB, ONCO: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Artelo Biosciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artelo Biosciences 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's 5-Year EBITDA Growth Rate falls into.


ARTL
31GF Score
Artelo Biosciences Inc ARTL
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artelo Biosciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 31.30% mean?
Artelo Biosciences (ARTL) has a 5-Year EBITDA Growth Rate of 31.30% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Artelo Biosciences and its competitors.
Is Artelo Biosciences' 5-Year EBITDA Growth Rate too high?
Artelo Biosciences' current 5-Year EBITDA Growth Rate is 31.30%. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' 5-Year EBITDA Growth Rate compare to REVB and MTNB?
Artelo Biosciences' 5-Year EBITDA Growth Rate of 31.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Artelo Biosciences and its competitors. Artelo Biosciences's current 5-Year EBITDA Growth Rate is 31.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current 5-Year EBITDA Growth Rate of 31.30%. The current 5-Year EBITDA Growth Rate is 31.30%. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current 5-Year EBITDA Growth Rate is 31.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artelo Biosciences Business Description

Address 505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score

Get the complete analysis for ARTL

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price